Lv3
224 积分 2022-05-28 加入
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
1个月前
已完结
非小细胞肺癌MET免疫组织化学检测和判读标准中国专家共识（2023版）
1个月前
已完结
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
1个月前
已完结
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
1个月前
已完结
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
1个月前
已完结
One peptide, two topologies: structure and interconversion dynamics of human uroguanylin isomers
6个月前
已完结
Antibody–drug conjugates come of age in oncology
6个月前
已完结
抗体药物偶联物治疗恶性肿瘤临床应用中国专家共识(2023版)
6个月前
已完结
抗体偶联药物安全性跨学科管理中国专家共识(2023)
6个月前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
10个月前
已完结
皖公网安备34019202002308
